一分钟看懂
这是一项关于肺癌的II 期研究，登记的药物或干预包括Firmonertinib；Definitive Thoracic Radiotherapy，当前状态为招募中。登记地点显示中国长沙有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Firmonertinib；Definitive Thoracic Radiotherapy · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Hunan Cancer Hospital · 长沙
公开的入选条件
- 1. Provision of informed consent prior to any study-specific procedures;
- 2. Age ≥18years;
- 3. ECOG performance status of 0 or 1 with no deterioration within the 2 weeks prior to enrollment, and a life expectancy of ≥12 weeks;
- 4. Histologically or cytologically confirmed non-squamous non-small cell lung cancer;
- 5. Assessed as having unresectable or inoperable locally advanced non-squamous non-small cell lung cancer suitable for definitive radiotherapy (Stage III according to AJCC 9th edition TNM staging);
- 6. Presence of EGFR uncommon mutations (excluding 19del, L858R, T790M) confirmed by genetic testing in a tertiary grade A hospital; specific types are detailed in Appendix 11;
- 7. No prior systemic anti-tumor therapy or radiotherapy for locally advanced non-small cell lung cancer before the first dose of the study drug, including chemotherapy, biologic therapy, targeted therapy, immunotherapy, or investigational drug therapy;
- 8. At least one accurately measurable lesion according to RECIST 1.1, which has not been previously irradiated and was not biopsied during the screening period. If a subject has only one measurable lesion, biopsy of that lesion is permitted, provided the basel
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07314216；登记信息更新于 2026-07-08。